UGUniversity of Georgia · Pharmacology
Breast Cancer Therapeutics Lab
Yaguang Xi · Athens, Georgia
Research Focus
Dr. Yaguang Xi's lab at the University of Georgia focuses on developing new therapies for difficult-to-treat breast cancer, particularly triple-negative breast cancer (TNBC). They are investigating a new compound called LG007, which has shown promise in shrinking tumors and inhibiting cancer spread in preclinical models. The lab combines molecular biology techniques with advanced animal models to understand the drug's actions and prepare for possible clinical trials.
triple-negative breast cancerLG007tumor growthmetastasismiR-10bPDX modelstherapeutic agentspharmacology
Research Aims
3AIM 01Determine the role of miR-10b and NR4A3 in the anti-cancer effects of LG007.
AIM 02Investigate the in vivo efficacy of LG007 using patient-derived xenograft models.
AIM 03Characterize the pharmacological and toxicological properties of LG007 for future clinical tests.
Skills the Lab Values
mouse modelsdrug efficacy testingin vivo studiesmolecular biology techniquesbiological assayspharmacological characterizationtoxicological assessmentdata analysis softwareexperimental design
Output against the department
Publications153bottom 43% of dept.263rd of 462
this lab
most publishedleast published
Citations6.2kbottom 44% of dept.257th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.